BACKGROUND: @entity740 ( @entity740 ) is @entity74 which is characterized by the presence of systemic low-grade @entity32 . There is also acquired @entity3230 in this @entity1 group which is clinically present with increased incidence of severe @entity281 , poor response to vaccination, and increased risk of @entity5 . Renal transplantation is one of the renal replacement modalities that restore renal functions. Mean platelet volume ( @entity6688 ) is emerging as a marker of @entity32 in many clinical conditions. In this study we aimed to disclose the improvement of paired immune response of ESRF @entity1 after renal transplantation even though they are under immunosuppressive therapy. METHODS: We retrospectively investigated C-reactive protein, @entity6688 , platelets (PLT), and other hematologic parameters on the day of transplantation and at the end of the 1st and 2nd years after transplantation of 58 preemptive and 112 nonpreemptive renal transplant @entity1 . We compared them with a healthy control group. RESULTS: The @entity6688 of the control group was 8.00    0.73. The mean @entity6688 of transplant @entity1 before transplantation and at the end of the 1st and 2nd years after transplantation were 7.66    1.01, 8.06    0.97, and 8.20    0.84, respectively. The initial @entity6688 of the @entity1 group was statistically significantly lower than the control group (P  = .04). There was a statistically significant increase of @entity6688 after transplantation. At the end of the 2nd year the difference of @entity6688 between the @entity1 and control groups was gone. CONCLUSIONS: We detected that @entity740 @entity1 had a decreased @entity6688 compared with normal individuals and that it normalized at the end of the 2nd year after renal transplantation. We speculated that the decreased @entity6688 in @entity740 @entity1 is related to increased @entity32 and uremic toxins owing to @entity5507 which was improved after renal transplantation.

High-Grade Inflammation in Renal Failure XXXX , According to Mean Platelet Volume, Improves at the End of Two Years After Transplantation.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity5 :: ('MESH:D009369', 'Disease') :: ['virus-associated cancers'] @entity5507 :: ('MESH:D014511', 'Disease') :: ['uremia'] @entity740 :: ('MESH:D051436', 'Disease') :: ['Chronic kidney disease', 'CKD'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity74 :: ('MESH:D030342', 'Disease') :: ['a worldwide disorder'] @entity6688 :: ('10244', 'Species') :: ['MPV'] @entity3230 :: ('MESH:C565469', 'Disease') :: ['immune deficiency']
@entity1 :: (9606,Species) :: ['Patients']
